Immunogenetic Predictors of Systemic Inflammatory Response Development in Diffuse Phlegmon of The Maxillofacial Region
Keywords:
Maxillofacial Region, Phlegmon, Cytokines, IL8 gene, Systemic ResponseAbstract
The study investigates the molecular genetic mechanisms of the development of purulent-inflammatory diseases of the maxillofacial region (MFR) in patients in Uzbekistan. A pathogenetic link was established between the -251T>A polymorphism of the IL8 gene and the severity of the systemic inflammatory response. It was proven that the TT genotype and T allele correlate with a critical increase in the concentration of pro-inflammatory cytokines (TNF-alpha up to 81.36 pg/ml, IL-8 up to 163.2 pg/ml), serving as early markers of diffuse phlegmon risk. The findings allow for objective prognosis and optimization of preventive therapy tactics.
References
[1] K. E. Shomurodov, “Features of the microbiological profile of purulent-inflammatory diseases of the maxillofacial region,” Journal of Theoretical and Clinical Medicine, no. 3, pp. 112–115, 2021.
[2] A. M. Gizatullina, “The role of genetic factors in the development of purulent-inflammatory diseases of the maxillofacial region,” Web of Medicine, vol. 2, pp. 45–50, 2024.
[3] K. E. Shomurodov, “Features of cytokine balance in the gingival fluid in odontogenic phlegmon of the maxillofacial region,” Vrach-aspirant (Postgraduate Doctor), no. 42(5.1), pp. 187–192, 2010.
[4] I. L. Vagina, N. S. Istomina, N. M. Khellinskaya, and Yu. B. Glazkov, “A modern approach to the complex treatment of patients with purulent-inflammatory diseases of the maxillofacial region,” Laser Medicine, vol. 17, no. 3, pp. 20–23, 2013.
[5] M. M. Isomov, K. E. Shomurodov, K. J. Olimjonov, and I. M. Azimov, “Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy (review of literature),” Biomedicine and Practice, no. SI-2, pp. 833–838, 2020.
[6] N. S. Kovaleva, A. S. Zabelin, and A. P. Zuzova, “Antibacterial therapy of purulent-inflammatory diseases of the maxillofacial region: A pharmacoepidemiological and clinico-microbiological study,” Clinical Microbiology and Antimicrobial Chemotherapy, vol. 13, no. 4, pp. 360–367, 2011.
[7] Sh. Yu. Abdullaev and K. E. Shomurodov, “Use of low-frequency ultrasound and Actovegin in the treatment of odontogenic phlegmon of the maxillofacial region,” Vrach-aspirant (Postgraduate Doctor), no. 46(3.3), pp. 454–459, 2011.
[8] V. S. Agapov and A. V. Davydov, Purulent-inflammatory diseases of the maxillofacial region and neck: A training manual. Moscow, Russia: Meditsina, 2018.
[9] E. A. Durnovo and N. V. Kudashkina, “Clinico-immunological features of purulent-inflammatory diseases of the maxillofacial region,” Medical Almanac, no. 3(43), pp. 152–155, 2016.
[10] V. M. Kaminsky and E. V. Sviridov, “Modern aspects of the treatment of odontogenic inflammatory diseases of the maxillofacial region,” Stomatology, vol. 98, no. 3, pp. 82–86, 2019.
[11] J. R. Hupp, E. Ellis, and M. R. Tucker, Contemporary Oral and Maxillofacial Surgery, 7th ed. St. Louis, MO, USA: Elsevier, 2019.
[12] M. Topazian and M. Goldberg, Oral and Maxillofacial Infections, 4th ed. Philadelphia, PA, USA: Saunders, 2002.
[13] P. A. Reichart and H. P. Philipsen, Odontogenic Tumors and Allied Lesions. London, UK: Quintessence Publishing, 2004.
[14] J. E. Peterson, “Principles of management of odontogenic infections,” Journal of Oral and Maxillofacial Surgery, vol. 71, no. 2, pp. 210–215, 2013.
[15] S. S. Jundt and A. Gutta, “Characteristics and cost impact of severe odontogenic infections,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 114, no. 5, pp. 558–566, 2012.
